Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 9/20 | 0.45 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21729501 | 1.00 | CYP2D6 (0.65) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL14443276 | 0.90 | CYP2D6 (0.66) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL20130443 | 0.88 | CYP2D6 (0.56) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL14846775 | 0.88 | CYP2D6 (0.65) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL1134617 | 0.85 | CYP2D6 (0.61) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL25056024 | 0.83 | CYP2D6 (0.51) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL12516687 | 0.83 | CYP2D6 (0.59) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL2229654 | 0.83 | CYP2D6 (0.59) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL22649470 | 0.83 | CYP2D6 (0.51) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL4182333 | 0.83 | CYP2D6 (0.59) | CYP2D6CA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838913-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREFOR | MabPlex International Co., Ltd. (CN) | 2021-06-23 | — | — | EP | disclosed |
| US-20190284149-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284149-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | AHR, ARNT, NR1H4 | CYP2D6 280/4885CA1 3103/4885CA2 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.